N Sarita Shah1, Sara C Auld1, James C M Brust1, Barun Mathema1, Nazir Ismail1, Pravi Moodley1, Koleka Mlisana1, Salim Allana1, Angela Campbell1, Thuli Mthiyane1, Natashia Morris1, Primrose Mpangase1, Hermina van der Meulen1, Shaheed V Omar1, Tyler S Brown1, Apurva Narechania1, Elena Shaskina1, Thandi Kapwata1, Barry Kreiswirth1, Neel R Gandhi1. 1. From the Emory University Rollins School of Public Health and School of Medicine (N.S.S., S.C.A., S.A., A.C., N.R.G.) and the Centers for Disease Control and Prevention (N.S.S.) - both in Atlanta; Albert Einstein College of Medicine and Montefiore Medical Center (N.S.S., J.C.M.B., N.R.G.), Columbia University Mailman School of Public Health (B.M., T.S.B.), and the American Museum of Natural History (A.N.) - all in New York; the National Institute for Communicable Diseases, Johannesburg (N.I., H.M., S.V.O.), University of KwaZulu-Natal and National Health Laboratory Service, Durban (P. Moodley, K.M., T.M., P. Mpangase), and the South African Medical Research Council, Cape Town (N.M., T.K.) - all in South Africa; and the Public Health Research Institute, New Jersey Medical School-Rutgers University, Newark (E.S., B.K.).
Abstract
BACKGROUND: Drug-resistant tuberculosis threatens recent gains in the treatment of tuberculosis and human immunodeficiency virus (HIV) infection worldwide. A widespread epidemic of extensively drug-resistant (XDR) tuberculosis is occurring in South Africa, where cases have increased substantially since 2002. The factors driving this rapid increase have not been fully elucidated, but such knowledge is needed to guide public health interventions. METHODS: We conducted a prospective study involving 404 participants in KwaZulu-Natal Province, South Africa, with a diagnosis of XDR tuberculosis between 2011 and 2014. Interviews and medical-record reviews were used to elicit information on the participants' history of tuberculosis and HIV infection, hospitalizations, and social networks. Mycobacterium tuberculosis isolates underwent insertion sequence (IS)6110 restriction-fragment-length polymorphism analysis, targeted gene sequencing, and whole-genome sequencing. We used clinical and genotypic case definitions to calculate the proportion of cases of XDR tuberculosis that were due to inadequate treatment of multidrug-resistant (MDR) tuberculosis (i.e., acquired resistance) versus those that were due to transmission (i.e., transmitted resistance). We used social-network analysis to identify community and hospital locations of transmission. RESULTS: Of the 404 participants, 311 (77%) had HIV infection; the median CD4+ count was 340 cells per cubic millimeter (interquartile range, 117 to 431). A total of 280 participants (69%) had never received treatment for MDR tuberculosis. Genotypic analysis in 386 participants revealed that 323 (84%) belonged to 1 of 31 clusters. Clusters ranged from 2 to 14 participants, except for 1 large cluster of 212 participants (55%) with a LAM4/KZN strain. Person-to-person or hospital-based epidemiologic links were identified in 123 of 404 participants (30%). CONCLUSIONS: The majority of cases of XDR tuberculosis in KwaZulu-Natal, South Africa, an area with a high tuberculosis burden, were probably due to transmission rather than to inadequate treatment of MDR tuberculosis. These data suggest that control of the epidemic of drug-resistant tuberculosis requires an increased focus on interrupting transmission. (Funded by the National Institute of Allergy and Infectious Diseases and others.).
BACKGROUND:Drug-resistant tuberculosis threatens recent gains in the treatment of tuberculosis and human immunodeficiency virus (HIV) infection worldwide. A widespread epidemic of extensively drug-resistant (XDR) tuberculosis is occurring in South Africa, where cases have increased substantially since 2002. The factors driving this rapid increase have not been fully elucidated, but such knowledge is needed to guide public health interventions. METHODS: We conducted a prospective study involving 404 participants in KwaZulu-Natal Province, South Africa, with a diagnosis of XDR tuberculosis between 2011 and 2014. Interviews and medical-record reviews were used to elicit information on the participants' history of tuberculosis and HIV infection, hospitalizations, and social networks. Mycobacterium tuberculosis isolates underwent insertion sequence (IS)6110 restriction-fragment-length polymorphism analysis, targeted gene sequencing, and whole-genome sequencing. We used clinical and genotypic case definitions to calculate the proportion of cases of XDR tuberculosis that were due to inadequate treatment of multidrug-resistant (MDR) tuberculosis (i.e., acquired resistance) versus those that were due to transmission (i.e., transmitted resistance). We used social-network analysis to identify community and hospital locations of transmission. RESULTS: Of the 404 participants, 311 (77%) had HIV infection; the median CD4+ count was 340 cells per cubic millimeter (interquartile range, 117 to 431). A total of 280 participants (69%) had never received treatment for MDR tuberculosis. Genotypic analysis in 386 participants revealed that 323 (84%) belonged to 1 of 31 clusters. Clusters ranged from 2 to 14 participants, except for 1 large cluster of 212 participants (55%) with a LAM4/KZN strain. Person-to-person or hospital-based epidemiologic links were identified in 123 of 404 participants (30%). CONCLUSIONS: The majority of cases of XDR tuberculosis in KwaZulu-Natal, South Africa, an area with a high tuberculosis burden, were probably due to transmission rather than to inadequate treatment of MDR tuberculosis. These data suggest that control of the epidemic of drug-resistant tuberculosis requires an increased focus on interrupting transmission. (Funded by the National Institute of Allergy and Infectious Diseases and others.).
Authors: V Ritacco; M Di Lonardo; A Reniero; M Ambroggi; L Barrera; A Dambrosi; B Lopez; N Isola; I N de Kantor Journal: J Infect Dis Date: 1997-09 Impact factor: 5.226
Authors: Elize Pietersen; Elisa Ignatius; Elizabeth M Streicher; Barbara Mastrapa; Xavier Padanilam; Anil Pooran; Motasim Badri; Maia Lesosky; Paul van Helden; Frederick A Sirgel; Robin Warren; Keertan Dheda Journal: Lancet Date: 2014-01-17 Impact factor: 79.321
Authors: Carole Mitnick; Jaime Bayona; Eda Palacios; Sonya Shin; Jennifer Furin; Felix Alcántara; Epifanio Sánchez; Madeleny Sarria; Mercedes Becerra; Mary C Smith Fawzi; Saidi Kapiga; Donna Neuberg; James H Maguire; Jim Yong Kim; Paul Farmer Journal: N Engl J Med Date: 2003-01-09 Impact factor: 91.245
Authors: N Sarita Shah; Courtney M Yuen; Moonseong Heo; Arielle W Tolman; Mercedes C Becerra Journal: Clin Infect Dis Date: 2013-09-24 Impact factor: 9.079
Authors: J A Guerra-Assunção; A C Crampin; R M G J Houben; T Mzembe; K Mallard; F Coll; P Khan; L Banda; A Chiwaya; R P A Pereira; R McNerney; P E M Fine; J Parkhill; T G Clark; J R Glynn Journal: Elife Date: 2015-03-03 Impact factor: 8.140
Authors: Louis Grandjean; Robert H Gilman; Laura Martin; Esther Soto; Beatriz Castro; Sonia Lopez; Jorge Coronel; Edith Castillo; Valentina Alarcon; Virginia Lopez; Angela San Miguel; Neyda Quispe; Luis Asencios; Christopher Dye; David A J Moore Journal: PLoS Med Date: 2015-06-23 Impact factor: 11.069
Authors: Yuri F van der Heijden; Fareed Abdullah; Bruno B Andrade; Jason R Andrews; Devasahayam J Christopher; Julio Croda; Heather Ewing; David W Haas; Mark Hatherill; C Robert Horsburgh; Vidya Mave; Helder I Nakaya; Valeria Rolla; Sudha Srinivasan; Retna Indah Sugiyono; Cesar Ugarte-Gil; Carol Hamilton Journal: Tuberculosis (Edinb) Date: 2018-10-01 Impact factor: 3.131
Authors: John Z Metcalfe; Elizabeth Streicher; Grant Theron; Rebecca E Colman; Christopher Allender; Darrin Lemmer; Rob Warren; David M Engelthaler Journal: Am J Respir Crit Care Med Date: 2017-11-01 Impact factor: 21.405
Authors: Kristin N Nelson; N Sarita Shah; Barun Mathema; Nazir Ismail; James C M Brust; Tyler S Brown; Sara C Auld; Shaheed Vally Omar; Natashia Morris; Angie Campbell; Salim Allana; Pravi Moodley; Koleka Mlisana; Neel R Gandhi Journal: J Infect Dis Date: 2018-11-05 Impact factor: 5.226
Authors: Sara C Auld; N Sarita Shah; Barun Mathema; Tyler S Brown; Nazir Ismail; Shaheed Vally Omar; James C M Brust; Kristin N Nelson; Salim Allana; Angela Campbell; Koleka Mlisana; Pravi Moodley; Neel R Gandhi Journal: Eur Respir J Date: 2018-10-18 Impact factor: 16.671
Authors: Argita D Salindri; Rose-Marie F Sales; Lauren DiMiceli; Marcos C Schechter; Russell R Kempker; Matthew J Magee Journal: Ann Am Thorac Soc Date: 2018-03
Authors: Max R O'Donnell; Michelle H Larsen; Tyler S Brown; Paras Jain; Vanisha Munsamy; Allison Wolf; Lorenzo Uccellini; Farina Karim; Tulio de Oliveira; Barun Mathema; William R Jacobs; Alexander Pym Journal: Antimicrob Agents Chemother Date: 2019-03-27 Impact factor: 5.191